7 October 2019 - The $40 million boost to PHARMAC's funding has paid for three new medicines to be available for New Zealanders, including two cancer drugs.

Health Minister David Clark announced on Monday that from December 1, PHARMAC will fund the drug Alecensa that fights advanced non-small cell lung cancer, and breast cancer drug Kadcyla.

A new treatment for multiple sclerosis, Ocrevus, is also being funded, and access to respiratory disease treatment Esbriet is being widened, the minister said.

Read Newshub article